Mark J. Ratain to Complement System Proteins
This is a "connection" page, showing publications Mark J. Ratain has written about Complement System Proteins.
Connection Strength
0.047
-
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
Score: 0.047